Prostaglandin receptor EP2 antagonists, derivatives, and uses related thereto
US12240829B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Mar 19, 2020 |
| Grant date | Mar 4, 2025 |
| Priority date | — |
| Expiry date | May 17, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D403/12
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The disclosure relates to Prostnglandin receptor EP2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in which EP2 receptor activation has a physiological role, such as but not limited to, brain injury, inflammatory diseases, epilepsy, neuroinflammation after a seizure, pain, endometriosis, cancer, rheumatoid arthritis, skin inflammation, vascular inflammation, colitis, and neurological disorders by administering a pharmaceutical composition comprising a compound disclosed herein to a subject in need thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.